# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
66743, Journal, 0, 21, "Diabetes Obes Metab .", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasJournal> \"Diabetes Obes Metab .\"."
1, PublicationYear, 22, 26, "2014", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasPublicationYear> \"2014\"."
2, Dapagliflozin, 106, 119, "Dapagliflozin", "", 
12, Title, 106, 281, "Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin .", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasTitle> \"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin .\"."
8, BodyWeight, 163, 169, "weight", "", 
112, Duration, 193, 200, "2 years", "", 
11, Precondition, 204, 279, "patients with type 2 diabetes mellitus inadequately controlled on metformin", "", "<http://ctro/data#Population_46152> <http://ctro/data#hasPrecondition> \"patients with type 2 diabetes mellitus inadequately controlled on metformin\"."
9, Type2Diabetes, 218, 242, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
10, Metformin, 270, 279, "metformin", "", 
13, Author, 282, 292, "Bolinder J", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Bolinder J\"."
14, Author, 301, 313, "Ljunggren Ö,", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Ljunggren Ö,\"."
15, Author, 314, 325, "Johansson L", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Johansson L\"."
16, Author, 328, 337, "Wilding J", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Wilding J\"."
17, Author, 340, 352, "Langkilde AM", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Langkilde AM\"."
18, Author, 355, 370, "Sj ö str ö m CD", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Sj ö str ö m CD\"."
19, Author, 373, 379, "Sugg J", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Sugg J\"."
20, Author, 382, 390, "Parikh S", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasAuthor> \"Parikh S\"."
21, Sweden, 553, 559, "Sweden", "", "<http://ctro/data#Population_46152> <http://ctro/data#hasCountry> <http://ctro/data#Sweden>."
132, ObjectiveDescription, 569, 790, "Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion .", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasObjectiveDescription> \"Dapagliflozin , a highly selective inhibitor of sodium - glucose cotransporter 2 ( SGLT2 ) , reduces hyperglycaemia and weight in patients with type   2 diabetes mellitus ( T2DM ) by increasing urinary glucose excretion .\"."
3, Dapagliflozin, 569, 582, "Dapagliflozin", "", 
22, Hypoglycemia, 670, 684, "hyperglycaemia", "", 
23, BodyWeight, 689, 695, "weight", "", 
24, Type2Diabetes, 713, 739, "type   2 diabetes mellitus", "", 
25, Type2Diabetes, 742, 746, "T2DM", "", 
29, ObjectiveDescription, 791, 937, "Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasObjectiveDescription> \"Long - term glycaemic control , body composition and bone safety were evaluated in patients with T2DM after 102 weeks of dapagliflozin treatment .\"."
26, Type2Diabetes, 888, 892, "T2DM", "", 
28, Duration, 899, 908, "102 weeks", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasCTduration> \"102 weeks\"."
4, Dapagliflozin, 912, 925, "dapagliflozin", "", 
30, Randomized, 953, 963, "randomized", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
31, DoubleBlind, 966, 980, "double - blind", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
32, Placebo, 983, 990, "placebo", "", 
66748, Precondition, 1035, 1053, "patients with T2DM", "", 
33, Type2Diabetes, 1049, 1053, "T2DM", "", 
139, Mean, 1056, 1060, "mean", "", 
34, AvgAge, 1067, 1073, "60 . 7", "", "<http://ctro/data#Population_46152> <http://ctro/data#hasAvgAge> \"60 . 7\"."
35, HbA1c, 1082, 1087, "HbA1c", "", 
44, BaseLineValue, 1088, 1093, "7 . 2", "", 
36, Percentage, 1094, 1095, "%", "", 
37, BMI, 1098, 1113, "body mass index", "", 
38, BMI, 1116, 1119, "BMI", "", 
45, BaseLineValue, 1122, 1128, "31 . 9", "", 
39, Kg_per_squareMeter, 1129, 1141, "kg / m ( 2 )", "", 
40, BodyWeight, 1144, 1155, "body weight", "", 
46, BaseLineValue, 1156, 1162, "91 . 5", "", 
41, Kg, 1163, 1165, "kg", "", 
66748, Precondition, 1168, 1204, "inadequately controlled on metformin", "", 
42, Metformin, 1195, 1204, "metformin", "", 
47, NumberPatientsCT, 1224, 1227, "182", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasNumberPatientsCT> \"182\"."
48, Randomized, 1235, 1243, "randomly", "", 
49, AllocationRatio, 1253, 1260, "1  :  1", "", "<http://ctro/data#AllocationRatio_46140> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_46140>."
5, Dapagliflozin, 1272, 1285, "dapagliflozin", "", "<http://ctro/data#Medication_46190> <http://ctro/data#hasDrug> <http://ctro/data#Dapagliflozin>."
50, DoseValue, 1286, 1288, "10", "", "<http://ctro/data#Medication_46190> <http://ctro/data#hasDoseValue> \"10\"."
51, mg, 1289, 1291, "mg", "", "<http://ctro/data#Medication_46190> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
52, Frequency, 1294, 1297, "day", "", "<http://ctro/data#Intervention_46178> <http://ctro/data#hasFrequency> \"day\"."
53, Placebo, 1301, 1308, "placebo", "", "<http://ctro/data#Intervention_46178> <http://ctro/data#hasFrequency> \"day\"."
56, OpenLabel, 1318, 1330, "open - label", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
54, Metformin, 1331, 1340, "metformin", "", 
57, Duration, 1347, 1356, "24 - week", "", 
58, DoubleBlind, 1357, 1371, "double - blind", "", 
162, Duration, 1403, 1412, "78 - week", "", 
163, DoubleBlind, 1413, 1441, "site - and patient - blinded", "", 
59, TimePoint, 1464, 1472, "week 102", "", 
63, TimePoint, 1488, 1496, "baseline", "", 
64, HbA1c, 1500, 1505, "HbA1c", "", 
65, BodyWeight, 1508, 1514, "weight", "", 
66, EndPointDescription, 1517, 1536, "waist circumference", "", 
67, EndPointDescription, 1539, 1558, "total body fat mass", "", 
68, MeasurementDevice, 1574, 1610, "dual - energy X - ray absorptiometry", "", "<http://ctro/data#MeasurementDevice_46255> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#MeasurementDevice>. <http://ctro/data#Endpoint_46251> <http://ctro/data#hasMeasurementDevice> <http://ctro/data#MeasurementDevice_46255>."
69, MeasurementDevice, 1613, 1616, "DXA", "", 
72, EndPointDescription, 1621, 1651, "serum markers of bone turnover", "", 
73, EndPointDescription, 1654, 1674, "bone mineral density", "", 
74, EndPointDescription, 1677, 1680, "BMD", "", 
70, MeasurementDevice, 1698, 1701, "DXA", "", 
71, EndPointDescription, 1708, 1722, "adverse events", "", 
75, FinalNumPatientsCT, 1761, 1764, "140", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasFinalNumberPatientsCT> \"140\"."
60, TimePoint, 1814, 1823, "102 weeks", "", "<http://ctro/data#Outcome_46261> <http://ctro/data#hasTimePoint> \"102 weeks\". <http://ctro/data#Outcome_46288> <http://ctro/data#hasTimePoint> \"102 weeks\". <http://ctro/data#Outcome_46315> <http://ctro/data#hasTimePoint> \"102 weeks\". <http://ctro/data#Outcome_46342> <http://ctro/data#hasTimePoint> \"102 weeks\". <http://ctro/data#Outcome_46369> <http://ctro/data#hasTimePoint> \"102 weeks\"."
6, Dapagliflozin, 1826, 1839, "dapagliflozin", "", 
76, HbA1c, 1880, 1885, "HbA1c", "", "<http://ctro/data#Endpoint_46236> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
77, Reduction, 1891, 1896, "0 . 3", "", "<http://ctro/data#Outcome_46261> <http://ctro/data#hasChangeValue> \"0 . 3\"."
81, Percentage, 1897, 1898, "%", "", "<http://ctro/data#Endpoint_46236> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
82, BodyWeight, 1901, 1907, "weight", "", "<http://ctro/data#Endpoint_46241> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
78, Reduction, 1913, 1919, "4 . 54", "", "<http://ctro/data#Outcome_46288> <http://ctro/data#hasChangeValue> \"4 . 54\"."
83, Kg, 1920, 1922, "kg", "", "<http://ctro/data#Endpoint_46241> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
85, EndPointDescription, 1925, 1944, "waist circumference", "", "<http://ctro/data#EndPointDescription_46247> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_46246> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_46247>."
79, Reduction, 1950, 1955, "5 . 0", "", "<http://ctro/data#Outcome_46315> <http://ctro/data#hasChangeValue> \"5 . 0\"."
87, BioAndMedicalUnit, 1956, 1958, "cm", "", "<http://ctro/data#BioAndMedicalUnit_46249> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_46246> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_46249>."
86, EndPointDescription, 1963, 1971, "fat mass", "", "<http://ctro/data#EndPointDescription_46252> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_46251> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_46252>."
80, Reduction, 1977, 1983, "2 . 80", "", "<http://ctro/data#Outcome_46342> <http://ctro/data#hasChangeValue> \"2 . 80\"."
84, Kg, 1984, 1986, "kg", "", "<http://ctro/data#Endpoint_46251> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
88, ObservedResult, 1987, 2003, "without increase", "", "<http://ctro/data#Outcome_46369> <http://ctro/data#hasObservedResult> \"without increase\"."
89, Hypoglycemia, 2015, 2028, "hypoglycaemia", "", "<http://ctro/data#Endpoint_46256> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
90, Placebo, 2045, 2052, "placebo", "", 
98, ObservedResult, 2055, 2076, "no meaningful changes", "", 
91, TimePoint, 2082, 2090, "baseline", "", 
196, EndPointDescription, 2094, 2118, "markers of bone turnover", "", 
93, EndPointDescription, 2122, 2125, "BMD", "", 
61, TimePoint, 2147, 2156, "102 weeks", "", 
194, NumberAffected, 2159, 2162, "One", "", "<http://ctro/data#Outcome_46401> <http://ctro/data#hasNumberAffected> \"One\". <http://ctro/data#Outcome_46428> <http://ctro/data#hasNumberAffected> \"One\"."
96, EndPointDescription, 2163, 2171, "fracture", "", "<http://ctro/data#EndPointDescription_46397> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_46396> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_46397>."
94, EndPointDescription, 2224, 2247, "urinary tract infection", "", 
95, EndPointDescription, 2250, 2253, "UTI", "", 
97, EndPointDescription, 2260, 2277, "genital infection", "", 
66752, ObservedResult, 2278, 2314, "was similar in both treatment groups", "", 
106, ConclusionComment, 2331, 2535, "Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .", "", "<http://ctro/data#ClinicalTrial_46136> <http://ctro/data#hasConclusionComment> \"Over 102 weeks , dapagliflozin improved glycaemic control , and reduced weight and fat mass , without affecting markers of bone turnover or BMD in patients with T2DM inadequately controlled on metformin .\"."
66753, TimePoint, 2336, 2345, "102 weeks", "", 
7, Dapagliflozin, 2348, 2361, "dapagliflozin", "", 
101, BodyWeight, 2403, 2409, "weight", "", 
102, EndPointDescription, 2414, 2422, "fat mass", "", 
103, EndPointDescription, 2443, 2467, "markers of bone turnover", "", 
104, EndPointDescription, 2471, 2474, "BMD", "", 
27, Type2Diabetes, 2492, 2496, "T2DM", "", 
55, Metformin, 2524, 2533, "metformin", "", 
107, PMID, 2604, 2612, "23906445", "", "<http://ctro/data#Publication_46129> <http://ctro/data#hasPMID> \"23906445\"."
